Results 91 to 100 of about 25,935 (265)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Nature Communications, 2021
Antibodies targeting a tumor antigen, GD2, show some efficacy for neuroblastoma but induce severe neuropathic pain and peripheral neuropathy. Here the authors design a gated chimeric antigen receptor (CAR), using GD2 as the gate and another tumor antigen,
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh   +9 more
doaj   +1 more source

A note on patch-based low-rank minimization for fast image denoising [PDF]

, 2018
Patch-based low-rank minimization for image processing attracts much attention in recent years. The minimization of the matrix rank coupled with the Frobenius norm data fidelity can be solved by the hard thresholding filter with principle component ...
Froment, Jacques, Hu, Haijuan, Liu, Quansheng   +2 more
core   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

GD2-Specific CAR T Cells Demonstrate Potent and Targeted Anti-Tumor Efficacy Against Melanoma In Vitro and In Vivo

Frontiers in Bioscience-Landmark
Background: Disialoganglioside (GD2) is a tumor-associated antigen that is highly expressed in various neuroectodermal cancers, including melanoma.
Julia Philippova, Julia Shevchenko, Alaa Alsalloum, Marina Fisher, Saleh Alrhmoun, Roman Perik-Zavodskii, Olga Perik-Zavodskaia, Julia Lopatnikova, Vasily Kurilin, Marina Volynets, Evgenii Zavjalov, Olga Solovieva, Hiroshi Shiku, Sergey Sennikov   +13 more
doaj   +1 more source

Inhomogeneous ferrimagnetic-like behavior in Gd2/3Ca1/3MnO3 single crystals

, 2008
We present a study of the magnetic properties of Gd2/3Ca1/3MnO3 single crystals at low temperatures. We show that this material behave as an inhomogeneous ferrimagnet.
D. Franco, David, G. Nieva, Gor’kov, Lee, Maignan, Mathieu, N. Haberkorn, Niebieskikwiat, Nogués, Pena, Qian, Radaelli, S. Larrégola, Saurel, Smolyaninova, Snyder, Tao, Webb, Wu, Zhou   +20 more
core   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

Nature Communications
Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment ...
Guillem Pascual-Pasto, Brendan McIntyre, Margaret G. Hines, Anna M. Giudice, Laura Garcia-Gerique, Jennifer Hoffmann, Pamela Mishra, Stephanie Matlaga, Simona Lombardi, Rawan Shraim, Patrick M. Schürch, Mark Yarmarkovich, Ted J. Hofmann, Fatemeh Alikarami, Daniel Martinez, Matthew Tsang, Luis Gil-de-Gómez, Timothy T. Spear, Kathrin M. Bernt, Adam J. Wolpaw, Dimiter S. Dimitrov, Wei Li, Kristopher R. Bosse   +22 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Electronic transport, structure, and energetics of endohedral Gd@C82 metallofullerenes

, 2004
Electronic structure and transport properties of the fullerene C$_{82}$ and the metallofullerene Gd@C$_{82}$ are investigated with density functional theory and the Landauer-Buttiker formalism.
Ardavan A., Becke A. D., Bethune D., Cotton F. A., Crabtree R. H., Cundari T. R., Datta S., Dolg M., Frisch M. J., Funasaka H., Funasaka H., Furukawa K., Hirahara K., Huang H., Huang H. J., Kant A., Kobayashi K., Kobayashi K., Lee C., Lee J., Nadaï C. D., Nishibori E., Nishihori E., Nishihori E., Okazaki T., Pagliara S., Parr R. G., Pati R., Perdew J. P., Reed A. E., Shimada T., Shinohara H., Suenaga K., Szabo A., Takata M., Tian W., Yerulshalmi R.   +36 more
core   +1 more source